Journal of Rheumatic Diseases

Table. 1.

Baseline clinical characteristics

Variable Male (n=85) Female (n=16) p-value
Age at disease onset (yr) 26.6±10.8 31.4±9.7 0.100
Age at estrogen sampling (yr) 38.3±11.4 39.3±8.8 0.739
Disease duration (mo) 55.6±66.7 29.3±29.0 0.126
Peripheral arthritis 38 (44.7) 7 (43.8) 0.944
Hip involvement 19 (22.4) 2 (12.5) 0.512
Uveitis 23 (27.1) 4 (25.0) 1.000
Enthesitis 12 (14.1) 2 (12.5) 1.000
mSASSS, initial 8.9±11.2 4.0±3.2 0.001
mSASSS, final 20.3±21.9 10.9±9.3 0.188
Sacroiliitis grade* 5.5±1.6 5.1±1.5 0.337
E2 (pg/mL) 114.1±35.9 108.8±45.7 0.552
Dkk1 (ng/mL) 1,243.5±760.4 962.0±521.7 0.160
Leptin (pg/mL) 1,896.1±1,847.5 2,968.5±2,361.3 0.045
ESR, initial (mm/h) 51.9±31.9 60.2±39.7 0.361
CRP, initial (mg/dL) 3.17±3.68 1.93±2.07 0.196
BMI (kg/m2) 24.6±3.8 22.2±2.7 0.018
Anti-TNF use 74 (87.1) 12 (75.0) 0.250
Current smoker 31 (36.5) 0 (0.0) 0.002
X-ray follow-up duration (mo) 97.2±60.9 58.5±54.3 0.020

Data are expressed as mean±standard deviation or number (%). mSASSS: modified Stoke Ankylosing Spondylitis Spine Score, E2: 17β-estradiol, Dkk1: dickkopf-1, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, BMI: body mass index, TNF: tumor necrosis factor. *Sacroiliitis grade refers to the sum of sacroiliitis grades of each side according to the modified New York criteria. Reference range for E2 are 0∼400 pg/mL.

J Rheum Dis 2021;28:76~84 https://doi.org/10.4078/jrd.2021.28.2.76
© J Rheum Dis